Medscape Oncology
By Medscape
To listen to an audio podcast, mouse over the title and click Play. Open iTunes to download and subscribe to podcasts.
Description
Latest medical news and features from Medscape Oncology
| Name | Description | Released | Price | ||
|---|---|---|---|---|---|
|
1 |
CleanCancer Drugs Not Working Hard Enough for the Money | Dr Peter Bach attributes the high cost of cancer drugs to the pharmaceutical industry's 'government-granted monopoly pricing power,' saying that benefit to patients is not commensurate with price. | 7/10/2017 | Free | View in iTunes |
|
2 |
CleanPotential ASCO Practice-Changers in HER2+ Breast Cancer | Oncologists will debate the APHINITY trial data for years to come, says Dr Kevin Kalinsky. | 7/7/2017 | Free | View in iTunes |
|
3 |
CleanCultivating Resiliency and Combating Burnout in Oncology | At ASCO 2017, experts provided practical tips for oncologists to develop resilience and prevent burnout in their professional lives. | 6/30/2017 | Free | View in iTunes |
|
4 |
CleanCultivating Resiliency and Combating Burnout in Oncology | At ASCO 2017, experts provided practical tips for oncologists to develop resilience and prevent burnout in their professional lives. | 6/30/2017 | Free | View in iTunes |
|
5 |
CleanA New Standard for Low-Grade Serous Cancer of the Ovary? | Dr Maurie Markman discusses new research on therapy for low-grade serous cancer of the ovary from the Journal of Clinical Oncology. | 6/29/2017 | Free | View in iTunes |
|
6 |
CleanNew ASCO Guideline for NSCLC: 'Precision Medicine at Its Best' | According to Dr Kris, new ASCO guidelines for adjuvant management of NSCLC stress the importance of multimodality care. | 6/27/2017 | Free | View in iTunes |
|
7 |
CleanNew CDK4/6i Data Move Metastatic Breast Cancer Field Forward | At ASCO 2017, the MONARCH-3, PALOMA-1, AND TREnd trials shed light on the efficacy of new CDK4/6 inhibitors for metastatic breast cancer. | 6/27/2017 | Free | View in iTunes |
|
8 |
CleanWill pCR and Pembro Redefine Breast Cancer Treatment? | Dr Laura Esserman discusses the ground-breaking I-SPY breast cancer research platform and its most 'exciting' results to date, indicating that pembrolizumab triples pCR in TNBC. | 6/19/2017 | Free | View in iTunes |
|
9 |
CleanOlympiAD: Olaparib Captures Gold for BRCA Breast Cancer | Study author Dr Susan Domchek discusses the positive results of the OlympiAD trial, presented at the ASCO plenary session, indicating olaparib as a strong option in metastatic breast cancer. | 6/12/2017 | Free | View in iTunes |
|
10 |
CleanGood IDEA: Drop Adjuvant Chemo From 6 to 3 Months in CRC | Dr John Marshall reports on the practice-changing results of the IDEA study in stage III colorectal cancer looking at duration of adjuvant chemotherapy, as presented at the ASCO plenary session. | 6/12/2017 | Free | View in iTunes |
|
11 |
CleanTop Melanoma Studies to Be Presented at ASCO | Dr Jeffrey Weber previews five melanoma treatment studies that he considers the ones to watch; one, he predicts, will be practice-changing. | 5/26/2017 | Free | View in iTunes |
|
12 |
CleanWill Adjuvant Oxaliplatin Data Change Practice in CRC? | Dr John Marshall previews the GI cancer studies being presented at ASCO with his picks for the ones to watch, and predicts that a plenary presentation may be practice-changing. | 5/26/2017 | Free | View in iTunes |
|
13 |
CleanTwo 'P' Words Top List of Hot Topics in Breast Cancer | Dr Kathy Miller points to PARP inhibitors and pertuzumab as highpoints of the breast cancer program at the upcoming ASCO meeting, including the plenary presentation of the OlympiAD trial. | 5/26/2017 | Free | View in iTunes |
|
14 |
CleanAdvances in Gynecologic Cancer: ASCO 2017 | Dr Markman previews the latest research on gynecologic cancer to be presented at the upcoming ASCO meeting. | 5/26/2017 | Free | View in iTunes |
|
15 |
CleanTalking With Patients About NGS Testing: Marketing vs Reality | Experts on genomic testing in cancer discuss the marketing of NGS tests, and how they talk to their patients in light of the promise of ‘precision medicine.’ | 5/19/2017 | Free | View in iTunes |
|
16 |
CleanWhat's New for Lung Cancer? Stay Tuned for ASCO 2017 | From targeted therapy to radiotherapy, Dr Mark Kris previews what's ahead for lung cancer management from ASCO 2017. | 5/15/2017 | Free | View in iTunes |
|
17 |
CleanExpert Panel: Should Genomic Testing Be Broadly Used in Cancer? | Experts respond to a Medscape survey of oncologists on the limits of genomic testing in cancer care. | 5/15/2017 | Free | View in iTunes |
|
18 |
CleanNew Approaches Needed for Peritoneal Metastases in CRC | Dr David Kerr challenges the oncology community to come up with rational, meaningful clinical trials to clarify the biology of metastatic peritoneal disease in colorectal cancer. | 4/13/2017 | Free | View in iTunes |
|
19 |
CleanAntineoplastic Agents in Breast Cancers With Mutational Signatures | Dr Markman encourages review of recently reported possible effect of ovarian cancer antineoplastic agents in breast cancer patients with rare BRCA mutational signatures. | 4/12/2017 | Free | View in iTunes |
|
20 |
CleanGauging Appropriate Care for Older Breast Cancer Patients | Reviewing the latest clinical management tools, Dr Arti Hurria talks about caring for the geriatric oncology patient long-term, without burning out. | 4/7/2017 | Free | View in iTunes |
|
21 |
CleanBiomarkers to Determine Who Gets Checkpoint Inhibitors | Reviewing recent research, Dr Jeffrey Weber concludes that an amalgam of host- and tumor-related markers will be the best indication of which patients should receive checkpoint inhibitors. | 4/3/2017 | Free | View in iTunes |
|
22 |
CleanImmuno-oncology in Colorectal Cancer: A Sneak Peek | Dr David J. Kerr reviews HDAC and immune checkpoint inhibitors, therapies on the horizon for a subset of patients with colorectal cancers. | 3/27/2017 | Free | View in iTunes |
|
23 |
CleanRucaparib 'Very Active' for High-Grade Ovarian Cancer | Dr Maurie Markman reports on high response rates to rucaparib therapy for ovarian cancer and looks forward to future research efforts using this PARP inhibitor. | 3/22/2017 | Free | View in iTunes |
|
24 |
CleanWhy the High CRC Rate in Latino--Genes, Stigma, or Other Factors? | Colorectal cancer is the second most common cause of cancer death in the Latino population. Drs John Marshall and Marcia Cruz-Correa discuss which factors are at play. | 3/20/2017 | Free | View in iTunes |
|
25 |
CleanRare Melanomas Prove 'Hard to Get' Using Immunotherapy | Dr Jeffrey Weber assesses the benefit of immunotherapies in two rare subtypes of melanoma and finds that rates of survival and duration of response trail well behind those associated with cutaneous melanoma. | 3/13/2017 | Free | View in iTunes |
|
26 |
CleanCase Presentation or Single-Patient Trial? | Dr David Kerr views a case of engineered T cells in a CRC patient with pulmonary metastases as an example of a single-patient clinical trial, neatly illustrating the potential of precision medicine. | 3/13/2017 | Free | View in iTunes |
|
27 |
CleanThe Puzzling Prognostic Effect of LDH in Melanoma | Although LDH is a negative prognostic factor in melanoma, patients who receive checkpoint inhibitors may still have responses of long duration even when their LDH level is high. | 3/6/2017 | Free | View in iTunes |
|
28 |
CleanRecurrent Colon Cancer: Location, Location, Location | Tumor location, whether on the right or left side of the colon, seems to affect the prognosis and aggressiveness of recurrent colorectal cancer. | 2/27/2017 | Free | View in iTunes |
|
29 |
CleanLow Recurrence After Risk-Reducing Surgery for BRCA Carriers | Dr Maurie Markman discusses the results of an RRSO surgery study showing a 1% incidence rate in long-term follow-up of subsequent peritoneal cancer. | 2/24/2017 | Free | View in iTunes |
|
30 |
CleanPractice Pearls: Checkpoint Inhibitors for Lung Cancer | Dr Mark Kris reviews the challenges of using newly approved immunotherapies for lung cancer patients, especially how to identify patients who will benefit and monitor their progress. | 2/23/2017 | Free | View in iTunes |
|
31 |
CleanSharing Genetic Data With Study Participants | Dr Maurie Markman explains that sharing genetic data with study participants encourages greater clinical trial involvement. | 1/31/2017 | Free | View in iTunes |
|
32 |
CleanEndocrine Therapy in Breast Cancer: Best Bet on Duration | Dr Harold Burstein reviews the latest data on duration of adjuvant endocrine therapy in metastatic breast cancer, and provides much-needed recommendations on how to approach the topic with patients. | 12/19/2016 | Free | View in iTunes |
|
33 |
CleanMyeloma Data at ASH 2016 Focus on Novel Combinations | The presentations at ASH 2016 for multiple myeloma focused on novel drug combinations in various settings, including newly diagnosed myeloma and refractory disease. | 12/12/2016 | Free | View in iTunes |
|
34 |
CleanNegative Trials, CAR T Studies Lead ASH Lymphoma Highlights | Drs Ann LaCasce and Kerry Savage discuss the most interesting lymphoma studies presented at ASH 2016, including the CALGB/Alliance 50303, GOYA, and GALLIUM trials. | 12/12/2016 | Free | View in iTunes |
|
35 |
CleanBurden of Cancer Pain Worse in Some Countries | One of the greatest worries of a cancer patient is the possibility of a painful death. Unfortunately, a painless death is not something that many oncologists around the world are able to promise. | 11/17/2016 | Free | View in iTunes |
|
36 |
CleanTwo Ipilimumab Trials Show Survival Benefit, and More Toxicity | Dr Weber discusses two studies that show a clear survival advantage with ipilimumab, but at a significant price in toxicity. | 10/31/2016 | Free | View in iTunes |
|
37 |
CleanBonanza of New Options for HR+/HER2- Breast Cancer | Patients with advanced HR-positive/HER2-negative breast cancer may benefit from practice-changing treatment options, as reported by Dr Javier Cortés from ESMO 2016. | 10/19/2016 | Free | View in iTunes |
|
38 |
CleanBig News: Adjuvant Ipi Improves Survival in Melanoma | Dr Caroline Robert reviews melanoma highlights from ESMO 2016, focusing on results of ipilimumab in the adjuvant setting and the highest 3-year survival achieved in metastatic disease. | 10/17/2016 | Free | View in iTunes |
|
39 |
CleanIs Immunotherapy Safe for Older Melanoma Patients? | How do adverse events from immunotherapy compare in younger vs older patients? Dr Weber comments on the safety of checkpoint inhibitors for our older patients. | 9/22/2016 | Free | View in iTunes |
|
40 |
CleanBiosimilars: Can They Be Trusted? | How similar are biosimilars to the index drug? Drs David Kerr and Håkan Mellstedt talk about how biosimilars are developed, regulated, and priced -- and whether they can be trusted by physicians. | 9/2/2016 | Free | View in iTunes |
|
41 |
CleanIconoclastic Breast Surgeon Laura Esserman Challenges the Status Quo | From screening to treatment, breast cancer specialist Laura Esserman is on a quest to individualize patient care, and in doing so she is challenging a number of long-standing practices in cancer care. | 8/8/2016 | Free | View in iTunes |
|
42 |
CleanAlleviate Cancer Survivor Distress: Screening and Psychosocial Care | Healthcare providers have a role in improving psychosocial outcomes of cancer survivors by identifying and addressing distress. | 6/20/2016 | Free | View in iTunes |
|
43 |
CleanFindings From NEMO, and Other Melanoma Highlights | In a preview of ASCO melanoma studies, the NEMO results suggest that binimetinib is reasonable for NRAS-mutated melanoma, and combo regimens continue to show strong outcomes, reports Dr Jeffrey Weber. | 5/31/2016 | Free | View in iTunes |
|
44 |
CleanAwesome Tips for Navigating ASCO and Chicago | Dr Sheetal Kircher gives tips for making the most out of the American Society of Clinical Oncology (ASCO) annual meeting and enjoying her hometown, Chicago. | 5/23/2016 | Free | View in iTunes |
|
45 |
CleanCould Diet Improve Outcomes in Glioblastoma? | Dr Alan Jacobs discusses an experimental study evaluating a high-fat, low-carbohydrate diet in mice with glioblastoma. | 5/13/2016 | Free | View in iTunes |
|
46 |
CleanMelanoma: ‘Tail’ on Survival Curve Is Getting Longer | Dr Jeffrey Weber, Medscape's new commentator on melanoma and immunotherapy, discusses impressive data on overall survival and combination therapy presented at AACR 2016. | 4/28/2016 | Free | View in iTunes |
|
47 |
CleanA Biotech Billionaire's Cancer 'Moonshot' | By leading an unprecedented group of companies, institutions, and scientists in Cancer Moonshot 2020, Patrick Soon-Shiong has set out to change cancer care forever. Here's how he plans to do it. | 4/20/2016 | Free | View in iTunes |
|
48 |
CleanBenefits of Additional Chemo in Residual Breast Cancer | Drs Kathy Miller and Bryan Schneider discuss the surprising CREATE-X findings, which show improved survival using more chemotherapy in triple-negative breast cancer patients with residual disease. | 2/29/2016 | Free | View in iTunes |
|
49 |
CleanOncology Burnout: 'Discretionary Time'--What's That? | Does the Medscape Lifestyle Report reflect the real issues of oncologists? Dr Sheetal Kircher takes a survey of her colleagues and finds work-life balance is hard to achieve at all stages of a career. | 2/12/2016 | Free | View in iTunes |
| 49 Items |
Listeners also subscribed to
- Journal of Oncology Practice Podcast
- Journal of Oncology Practice
- View in iTunes
- Listen to The Lancet Oncology
- The Lancet Oncology
- View in iTunes
- Journal of Clinical Oncology (JCO) Podcast
- Journal of Clinical Oncology (JCO)
- View in iTunes
- PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
- PVI, PeerView Institute for Medical Education
- View in iTunes